Cell and Gene Commercialization

31. Plan How To Get To Market Quickly, Post Proof-Of-Concept 12/2/2024

    This episode of the De-risking Drug Development series focuses on accelerating drug development and enhancing product differentiation through innovative trial design.

32. Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases 11/26/2024

    EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.

33. RNA Therapeutics: New Market Research 11/14/2024

    According to our new market research, the RNA therapeutics industry is predicted to exceed $31 billion by 2032. This article shares key findings and trends.

34. Leveraging Platform And Process Characterization Data To Accelerate CGT Validation And Commercialization 11/12/2024

    Accelerate the delivery of cell and gene therapies by adopting streamlined validation and leveraging strategies that reduce timelines and support sustainable, compliant manufacturing pipelines.

35. Perspectives On Performance, Scalability, And Regulatory Compliance 10/28/2024

    Here, we discuss the challenges and solutions for cell and gene therapies, focusing on performance, scalability, and regulatory compliance to accelerate commercialization and improve patient access.

36. Highlights From ARM's 2024 Meeting On The Mesa 10/25/2024

    ARM's 2024 Meeting on the Mesa has concluded. Here are a few brief highlights from this year's conference.

37. How Platform Technologies Are Shaping The Gene Therapy Landscape 9/30/2024

    Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward.

38. Adapting A rcAAV Assay For Commercial Manufacturing 9/16/2024

    Better understand the intricacies of AAV triple transfection and how advances in vector production and cell line optimization are enhancing gene therapy.

39. Increasing The CGT Field's Investment In Innovation 9/13/2024

    In this segment from the Cell & Gene Live! Event Modernizing CAR-T Manufacturing: Is Point Of Care The Future?, our expert panelists respond to an audience question about how the industry can increase investment in the field’s innovation.

40. The Future Of Autologous CAR-T Manufacturing: Balancing Innovation With Improvement 9/12/2024

    Experts from last month's Cell & Gene Live event discuss the innovations seen in CAR-T manufacturing and shared their thoughts on the feasibility of decentralized and point-of-care models to address manufacturing challenges.